Quantifying Antibody Persistence After a Single Dose of COVID‐19 Vaccine Ad26.COV2.S in Humans Using a Mechanistic Modeling and Simulation Approach
Open Access
- 9 December 2022
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 113 (2) , 380-389
Abstract
Understanding persistence of humoral immune responses elicited by vaccination against coronavirus disease 2019 (COVID‐19) is critical for informing the duration of protection and appropriate booster timing. We developed a mechanistic model to characterize the time course of humoral immune responses in severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2)–seronegative adults after primary vaccination with the Janssen COVID‐19 vaccine, Ad26.COV2.S. The persistence of antibody responses was quantified through mechanistic modeling‐based simulations. Two biomarkers of humoral immune responses were examined: SARS‐CoV‐2 neutralizing antibodies determined by wild‐type virus neutralization assay (wtVNA) and spike protein‐binding antibodies determined by indirect spike protein enzyme‐linked immunosorbent assay (S‐ELISA). The persistence of antibody responses was defined as the period of time during which wtVNA and S‐ELISA titers remained above the lower limit of quantification. A total of 442 wtVNA and 1,185 S‐ELISA titers from 82 and 220 participants, respectively, were analyzed following administration of a single dose of Ad26.COV2.S (5 × 1010 viral particles). The mechanistic model adequately described the time course of observed wtVNA and S‐ELISA serum titers and its associated variability up to 8 months following vaccination. Mechanistic model‐based simulations show that single‐dose Ad26.COV2.S elicits durable but waning antibody responses up to 24 months following immunization. Of the estimated model parameters, the production rate of memory B cells was decreased in older adults relative to younger adults, and the antibody production rate mediated by long‐lived plasma cells was increased in women relative to men. A steeper waning of antibody responses was predicted in men and in older adults.Keywords
This publication has 37 references indexed in Scilit:
- Model Evaluation of Continuous Data Pharmacometric Models: Metrics and GraphicsCPT: Pharmacometrics & Systems Pharmacology, 2016
- A model-based meta-analysis of monoclonal antibody pharmacokinetics to guide optimal first-in-human study designmAbs, 2014
- Living on Three Time Scales: The Dynamics of Plasma Cell and Antibody Populations Illustrated for Hepatitis A VirusPLOS Computational Biology, 2012
- Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects ModelsThe AAPS Journal, 2011
- On Identifiability of Nonlinear ODE Models and Applications in Viral DynamicsSIAM Review, 2011
- Importance of Shrinkage in Empirical Bayes Estimates for Diagnostics: Problems and SolutionsThe AAPS Journal, 2009
- Biodistribution and Toxicological Safety of Adenovirus Type 5 and Type 35 Vectored Vaccines Against Human Immunodeficiency Virus-1 (HIV-1), Ebola, or Marburg Are Similar Despite Differing Adenovirus Serotype Vector, Manufacturer's Construct, or Gene InsertsJournal of Immunotoxicology, 2008
- Mathematical model of the antibody response to hepatitis B vaccines: Implications for reduced schedulesVaccine, 2007
- Modelling Response Time Profiles in the Absence of Drug Concentrations: Definition and Performance Evaluation of the K–PD ModelJournal of Pharmacokinetics and Pharmacodynamics, 2006
- Building population pharmacokineticpharmacodynamic models. I. Models for covariate effectsJournal of Pharmacokinetics and Biopharmaceutics, 1992